| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.BERH.2008.09.008 |
| P698 | PubMed publication ID | 19028367 |
| P50 | author | Manuel Ramos-casals | Q42646201 |
| Munther A. Khamashta | Q73418907 | ||
| P2093 | author name string | Pilar Brito-Zerón | |
| Maria-Jose Cuadrado | |||
| Maria-Jose Soto | |||
| P433 | issue | 5 | |
| P921 | main subject | TNF | Q18032037 |
| P304 | page(s) | 847-861 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Best Practice & Research: Clinical Rheumatology | Q4896784 |
| P1476 | title | Autoimmune diseases induced by TNF-targeted therapies | |
| P478 | volume | 22 |
| Q42109511 | A Case of Sarcoidosis Associated With Anti-Tumor Necrosis Factor Treatment |
| Q92994177 | A Synthetic Gene Circuit for Self-Regulating Delivery of Biologic Drugs in Engineered Tissues |
| Q83163917 | A case of antisynthetase syndrome in a rheumatoid arthritis patient with anti-PL-12 antibody following treatment with etanercept |
| Q90219532 | A case of leukocytoclastic vasculitis associated with anti-tumor necrosis factor therapy |
| Q37814549 | A decade of infliximab: The Austrian evidence based consensus on the safe use of infliximab in inflammatory bowel disease. |
| Q35093044 | A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis |
| Q58770168 | A rare case of suicidal ideation related to Adalimumab use |
| Q34170097 | Accelerated atherosclerosis in systemic lupus erythematosus: role of proinflammatory cytokines and therapeutic approaches |
| Q37322146 | Acute renal artery occlusion following infliximab infusion |
| Q43107231 | Adalimumab (Humira) induced acute lung injury |
| Q33824393 | Adalimumab-induced acute interstitial lung disease in a patient with rheumatoid arthritis. |
| Q37768489 | Alopecia areata as another immune-mediated disease developed in patients treated with tumour necrosis factor-α blocker agents: Report of five cases and review of the literature. |
| Q36418745 | Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus(). |
| Q36337350 | Antiphospholipid-related chorea. |
| Q85324693 | Assessing the likelihood of new-onset inflammatory bowel disease following tumor necrosis factor-alpha inhibitor therapy for rheumatoid arthritis and juvenile rheumatoid arthritis |
| Q43129961 | Association of ANCA associated vasculitis and rheumatoid arthritis: a lesser recognized overlap syndrome |
| Q56974534 | Autoantibodies in psoriatic patients treated with anti-TNF-α therapy |
| Q47377327 | Autoimmune/inflammatory syndrome induced by adjuvants-ASIA-related to biomaterials: analysis of 45 cases and comprehensive review of the literature. |
| Q37390458 | Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs. |
| Q41120913 | Biologics in dermatology: adverse effects |
| Q55248042 | Bullous Pemphigoid Associated with Adalimumab Therapy in a Patient with Ulcerative Colitis. |
| Q34047602 | CRISPR/Cas9 Editing of Murine Induced Pluripotent Stem Cells for Engineering Inflammation-Resistant Tissues |
| Q38202641 | Certolizumab-induced uveitis: a case report and review of the literature |
| Q64100641 | Characterization of Blau syndrome panuveitis with wide-field fluorescein angiography |
| Q51553118 | Characterization of patients with infliximab-induced lupus erythematosus and outcomes after retreatment with a second anti-TNF agent. |
| Q47219412 | Chronic Inflammation Increases the Sensitivity of Mouse Treg for TNFR2 Costimulation |
| Q26829810 | Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients |
| Q38222882 | Current and prospective pharmacotherapy for autoimmune hepatitis |
| Q37994612 | Cytokine-based therapy in psoriasis |
| Q48192268 | Detrimental roles of TNF-alpha in the antiphospholipid syndrome and de novo synthesis of antiphospholipid antibodies induced by biopharmaceuticals against TNF-alpha. |
| Q34009656 | Digital vasculitis in a patient with rheumatoid arthritis responded well to adalimumab. |
| Q84675149 | Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis |
| Q48140916 | Diverse patterns of anti-TNF-α-induced lupus: case series and review of the literature |
| Q34180488 | Do selected drugs increase the risk of lupus? A matched case-control study |
| Q33563872 | Drug-induced autoimmune liver disease: A diagnostic dilemma of an increasingly reported disease. |
| Q37967416 | Drug-induced lupus anticoagulants and antiphospholipid antibodies |
| Q36579988 | Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents |
| Q38190033 | Drug-induced lupus: Including anti-tumour necrosis factor and interferon induced |
| Q51023399 | Drug-induced uveitis. |
| Q35127388 | Effect of tumor necrosis factor inhibitors on rheumatoid arthritis-induced peripheral neuropathy: A cohort study |
| Q37682722 | Emerging opportunities for site-specific molecular and cellular interventions in autoimmune hepatitis |
| Q57330601 | Etanercept induced organizing pneumonia in a patient with rheumatoid arthritis |
| Q39560913 | Etanercept-induced generalization of chronic, localized, anogenital bullous pemphigoid in a psoriatic patient |
| Q35803068 | Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment |
| Q37197925 | Exogenous TNFR2 activation protects from acute GvHD via host T reg cell expansion |
| Q58724935 | Expanding the Boundaries of Biotherapeutics with Bispecific Antibodies |
| Q38137819 | Frequency and spectrum of myopathies in patients with psoriasis |
| Q47697061 | Genome Engineering for Personalized Arthritis Therapeutics |
| Q42278257 | Genome Engineering of Stem Cells for Autonomously Regulated, Closed-Loop Delivery of Biologic Drugs |
| Q37162850 | Henoch-Schönlein Purpura with Adalimumab Therapy for Ulcerative Colitis: A Case Report and Review of the Literature. |
| Q33654733 | Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease |
| Q38315640 | Immune-mediated reactions to anti-tumor necrosis factors in inflammatory bowel disease |
| Q35206971 | Inhibition of soluble tumour necrosis factor is therapeutic in experimental autoimmune encephalomyelitis and promotes axon preservation and remyelination |
| Q37810403 | Involvement of the Immune System in Idiosyncratic Drug Reactions |
| Q51136025 | Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. |
| Q51066095 | Is there a role for TNFα blockade in ANCA-associated vasculitis and glomerulonephritis? |
| Q34722599 | Large Vessel Vasculitis Occurring in Rheumatoid Arthritis Patient under Anti-TNF Therapy |
| Q37789689 | Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease |
| Q61958829 | Lung Sarcoidosis Induced by TNF Antagonists in Rheumatoid Arthritis: A Case Presentation and a Literature Review |
| Q37632332 | Major involvement of bacterial components in rheumatoid arthritis and its accompanying oxidative stress, systemic inflammation and hypercoagulability |
| Q58134824 | Management Decisions for Rheumatoid Arthritis After Tumor Necrosis Factor Alpha Antagonist-Induced Lupus-Like Syndrome |
| Q37832130 | Monoclonal antibody therapy-associated neurological disorders |
| Q41687188 | Mortality in patients with interstitial lung disease treated with rituximab or TNFi as a first biologic |
| Q37830968 | Multicentric reticulohistiocytosis with dermatomyositis-like features: a more common disease presentation than previously thought |
| Q37911957 | New insights into gastrointestinal and hepatic granulomatous disorders |
| Q41256627 | New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease |
| Q59074825 | New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review |
| Q48140030 | No evidence for induction of autoantibodies or autoimmunity during treatment of psoriasis with ustekinumab. |
| Q37876945 | Palisaded neutrophilic and granulomatous dermatitis presenting in a patient with rheumatoid arthritis on adalimumab |
| Q35309470 | Pathogenesis and potential therapeutic targets in systemic lupus erythematosus: from bench to bedside |
| Q37778642 | Pathogenesis of cutaneous lupus erythematosus: common and different features in distinct subsets. |
| Q42127776 | Patients with inflammatory bowel disease have increased risk of autoimmune and inflammatory diseases. |
| Q59511343 | Personalization of biologic therapy in patients with rheumatoid arthritis: less frequently accounted choice-driving variables |
| Q39366732 | Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases. |
| Q21134119 | Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes |
| Q37345155 | Pulmonary complications of tumor necrosis factor-targeted therapy |
| Q38979324 | Regulation of Interleukin-23 Expression in Health and Disease |
| Q40674036 | Regulatory multitasking of tolerogenic dendritic cells - lessons taken from vitamin d3-treated tolerogenic dendritic cells |
| Q26822029 | Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease |
| Q54334835 | Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis. |
| Q37541561 | Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases |
| Q37737138 | Rituximab therapy in lupus nephritis: current clinical evidence |
| Q47226473 | Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. |
| Q36766536 | Sarcoidosis patient with lupus pernio and infliximab-induced myositis: Response to Acthar gel. |
| Q41146021 | Targeting IL-23: insights into the pathogenesis and the treatment of psoriasis |
| Q44803722 | The incidence and predictors of lupus-like reaction in patients with IBD treated with anti-TNF therapies |
| Q38785400 | Three cases of anti-TNF induced myositis and literature review |
| Q37778588 | Toxicity and Monitoring of Immunosuppressive Therapy Used in Systemic Autoimmune Diseases |
| Q55386131 | Tumor Necrosis Factor α and Regulatory T Cells in Oncoimmunology. |
| Q39039141 | Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review |
| Q34015824 | Tumor necrosis factor inhibitor-associated dermatomyositis |
| Q37795639 | Tumor necrosis factor-alpha (TNF-α)-blockade-induced hepatic sarcoidosis in psoriatic arthritis (PsA): case report and review of the literature |
| Q37831189 | Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies |
| Q37722841 | Vasculitis associated with rheumatoid arthritis: a case-control study |
| Q36513081 | Vasculitis associated with tumor necrosis factor-α inhibitors |
| Q36167360 | Weight Gain and Hair Loss during Anti-TNF Therapy |
Search more.